Search | Clinical Trials Finder

Conditions: Infections, Papillomavirus
Interventions: Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 11 Years to 18 Years · Female only
Enrollment: 1,330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more

Conditions: Meningococcal Immunisation (Healthy Volunteers)
Interventions: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 13 Years to 26 Years
Enrollment: 570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more

Conditions: Guillain-Barre Syndrome
Interventions: Not listed
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 11 Years to 21 Years
Enrollment: 6,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 6
States / cities: Wilmington, Delaware • Honolulu, Hawaii • Boston, Massachusetts + 3 more

Conditions: Vaccines, Meningococcal Vaccines
Interventions: rLP2086 + MCV4 + Tdap, MCV4 + Tdap + saline, rLP2086 + saline; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 12 Years
Enrollment: 2,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 117
States / cities: Birmingham, Alabama • Daphne, Alabama • Chandler, Arizona + 73 more

Conditions: Healthy Volunteers (Meningococcal Infection)
Interventions: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,797 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 67
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more

Conditions: Prevention of Meningococcal Disease
Interventions: MenACWY-CRM Vaccine, MenACWY-PS Vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 12 Months to 10 Years
Enrollment: 910 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Oakland, California

Conditions: Meningococcal Meningitis
Interventions: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine; Biological
Lead sponsor: Novartis; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • Fremont, California • Madera, California + 14 more

Conditions: Meningococcal Disease
Interventions: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 7 Years to 15 Years
Enrollment: 465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 10 more

Conditions: Infections, Meningococcal
Interventions: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 704 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 36
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more

Conditions: Meningitis, Meningococcemia, Neisseria Meningitidis
Interventions: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years to 5 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 8
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Woburn, Massachusetts + 5 more

Conditions: Gonorrhoea
Interventions: Meningococcal Group B Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Meningitis, Meningococcal Infection, Neisseria Meningitidis
Interventions: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Boca Raton, Florida + 12 more

Conditions: Meningitis, Meningococcal, Serogroup B
Interventions: 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine, 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Meningitis, Meningococcal
Interventions: MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more

Conditions: Infections, Meningococcal
Interventions: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 56
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more

Conditions: Meningitis, Meningococcal Infection
Interventions: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus; Biological
Lead sponsor: Novartis; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 7,744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 130
States / cities: Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more

Conditions: Meningitis, Meningococcal Infection
Interventions: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 834 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 15
States / cities: Little Rock, Arkansas • San Diego, California • Bardstown, Kentucky + 12 more

Conditions: Meningococcal Vaccines
Interventions: Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Meningococcal Disease
Interventions: MenABCWY, Placebo, MenACWY; Biological · Other
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: Meningococcal Disease
Interventions: Meningococcal ABCWY, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 19 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: Meningococcal Infections
Interventions: MenACWY-CRM, Licensed meningococcal ACWY vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 2,907 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 52
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more

Conditions: Meningitis, Meningococcal
Interventions: Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 2 Months to 2 Months
Enrollment: 4,545 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 53
States / cities: Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 56 Years and older
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more

Conditions: Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication, Satisfaction
Interventions: AFIX Only, AFIX+ Provider Communication Training; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Search by objective public record fields.

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Safety Study of GBS Following Menactra Meningococcal Vaccination

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Dose Comparison Study of Menactra® in US Children

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

High and Low Resource Interventions to Promote HPV Vaccines